4'-deoxy-4'-iodo-doxorubicinol

**4'-deoxy-4'-iodo-doxorubicinol** is the 13-dihydro derivative (major metabolite) of 4'-iodo-4'-deoxy-doxorubicin (IDOX), an *anthracycline* analog of doxorubicin. It was developed to address resistance and toxicity issues: the parent compound (IDOX) exhibits markedly greater potency than doxorubicin in sensitive and resistant cell lines, attributed to higher lipophilicity and faster cellular uptake[1][2]. In metabolism studies, **4'-deoxy-4'-iodo-doxorubicinol** was found at high levels following administration of IDOX, with an elimination half-life around 15 hours, and while active, it showed somewhat reduced cytotoxicity in resistant lines compared to the parent drug[1][3]. The mechanism of action is expected to be similar to other anthracyclines, involving intercalation into DNA and inhibition of topoisomerase II, thus blocking replication and inducing cytotoxicity.

Other names

4'-deoxy-4'-iodo-doxorubicinol4'-iodo-4'-deoxy-doxorubicinol